ENOV
$23.46
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Preventi...
Recent News
EHC Stock: Do Valuation and Expansion Trends Support a Hold Strategy?
EHC is expanding its inpatient rehab network and posting steady revenue and cash-flow growth, but Medicaid policy risks and higher debt remain concerns.
How The Enovis (ENOV) Story Is Shifting Around Growth Margins And Cash Generation
Enovis is working with an updated fair value estimate that edges from US$45.09 to US$45.18, a very small shift that still matters for anyone tracking the stock’s valuation anchor. Analysts are tying this move to the current mix of slightly softer revenue expectations, tighter earnings assumptions, and fresh commentary around free cash flow progress and execution risk. As you read on, you will see how these pieces fit together and how you can track the evolving narrative around Enovis for...
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.
Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - specialty stocks fared in Q4, starting with Enovis (NYSE:ENOV).
Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet
The mean of analysts' price targets for Enovis (ENOV) points to a 76.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.